Filament Health Corp. and ATMA Journey Centers announced the recent dosing of 14 healthy subjects with Filament's natural psilocybin drug candidate in a Health Canada-approved clinical trial as part of ATMA's psychedelic-assisted therapist training program. The trial's success reflects the operational calibre of both ATMA and Filament.